These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32256817)

  • 1. APOBEC3B expression and its prognostic potential in breast cancer.
    Mao Y; Lv M; Zhang Y; Nie G; Cui J; Wang Y; Wang Y; Cao W; Liu X; Wang X; Wang H
    Oncol Lett; 2020 Apr; 19(4):3205-3214. PubMed ID: 32256817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
    Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Fujiki Y; Yamamoto Y; Sueta A; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Tomiguchi M; Takeshita T; Iwase H
    Oncotarget; 2018 Jul; 9(55):30513-30526. PubMed ID: 30093965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
    Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
    PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
    Rüder U; Denkert C; Kunze CA; Jank P; Lindner J; Jöhrens K; Kulbe H; Sehouli J; Dietel M; Braicu E; Darb-Esfahani S
    Histol Histopathol; 2019 Apr; 34(4):405-417. PubMed ID: 30289149
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Sieuwerts AM; Doebar SC; de Weerd V; Verhoef EI; Beauford CM; Agahozo MC; Martens JWM; van Deurzen CHM
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
    Sieuwerts AM; Schrijver WA; Dalm SU; de Weerd V; Moelans CB; Ter Hoeve N; van Diest PJ; Martens JW; van Deurzen CH
    PLoS One; 2017; 12(1):e0171343. PubMed ID: 28141868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3B expression has prognostic significance in cervical cancer.
    Zhang SQ; Zhang J; Yu Y; Yu MM; Wei J; Tang YH
    Int J Clin Exp Pathol; 2023; 16(3):48-56. PubMed ID: 37033395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3.
    Gara SK; Tyagi MV; Patel DT; Gaskins K; Lack J; Liu Y; Kebebew E
    Oncotarget; 2020 Sep; 11(36):3354-3370. PubMed ID: 32934779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
    Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
    Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis.
    Wu J; Li N; Zhu L; Zhen D; Li M; Chen H; Ye M; Wei Y; Shao G
    BMC Bioinformatics; 2022 Aug; 23(1):312. PubMed ID: 35918642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer.
    Huo Q; Li Z; Cheng L; Yang F; Xie N
    Front Oncol; 2020; 10():621. PubMed ID: 32528869
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis.
    Kurozumi S; Matsumoto H; Kurosumi M; Inoue K; Fujii T; Horiguchi J; Shirabe K; Oyama T; Kuwano H
    Oncol Lett; 2019 Mar; 17(3):2647-2656. PubMed ID: 30867728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High WDR34 mRNA expression as a potential prognostic biomarker in patients with breast cancer as determined by integrated bioinformatics analysis.
    Hu DJ; Shi WJ; Yu M; Zhang L
    Oncol Lett; 2019 Sep; 18(3):3177-3187. PubMed ID: 31452794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
    BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.